Semaglutide 20mg Peptide
Research Use Only
Get Notified When Available
This product is currently out of stock. Enter your email and we'll notify you the moment it's back.
Research Use Only
For in vitro laboratory research by qualified professionals only. Not for human or animal administration. Not intended to treat, prevent, mitigate, or cure any disease. Batch-specific Certificates of Analysis available for all products.
Research Use Only
For in vitro laboratory research by qualified professionals only. Not for human or animal administration. Not intended to treat, prevent, mitigate, or cure any disease. Batch-specific Certificates of Analysis available for all products.
Semaglutide acts at GLP-1 receptors on pancreatic beta cells, hypothalamic appetite centres, the stomach and the intestine, producing glucose-dependent insulin secretion, glucagon suppression and delayed gastric emptying. It is the most extensively characterised molecule in the incretin class, which makes it the usual comparator when newer dual and triple agonists are evaluated. This 20mg vial doubles the material available per vial relative to the 10mg presentation, which reduces the number of reconstitutions in extended protocols and in multi-arm comparative studies.
Frequently Bought Together
Semaglutide 20mg
20mg
$79 USD
Bundle & Save
$179 USD
Save $9 USD
$244 USD
Save $24 USD
$289 USD
Save $44 USD
$389 USD
Save $79 USD
Click any product above to toggle selection
Related Peptides
Related Research News
Semaglutide News: Orthopedic Surgeon Shares Key Insights on Ozempic and Wegovy
Recent semaglutide news highlights an orthopedic surgeon's perspective on Ozempic and Wegovy. The report touches on weight loss efficacy and safety considerations, offering context for researchers and industry professionals tracking GLP-1 developments.
5 Mental Health Benefits of GLP-1 Drugs Like Ozempic and Wegovy: Latest Ozempic News
Recent reports highlight five mental health benefits associated with GLP-1 drugs like Ozempic and Wegovy, extending beyond weight loss. This analysis covers the implications for peptide researchers and the broader industry.
Semaglutide News: Novo Nordisk Wins Dutch Patent Injunction
Novo Nordisk has secured a Dutch court injunction in a semaglutide patent infringement case, according to recent reports. The decision adds a layer of legal protection for the drug, which is also marketed as Wegovy. This semaglutide news highlights ongoing efforts to safeguard intellectual property in the growing GLP-1 market.